Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0170 Phase 3 study in primary open angle glaucoma or ocular hypertension
jRCT2031240150Phase 3Active, not recruiting
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Simbrinza in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Senju Pharmaceutical Co., Ltd. Primary endpoint: Change in intraocular pressure from baseline. Started Jun 2024; status: active, not recruiting.
02
Drugs
Simbrinza
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2031240150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240150.